We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Idera Pharmaceuticals Inc | NASDAQ:IDRA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.425 | 0.432 | 0.48 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 5)*
Aceragen, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
00445F109
(CUSIP Number)
February 14, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
* | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
NAMES OF REPORTING PERSONS Castellina Ventures Ltd. CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☒ SEC USE ONLY CITIZENSHIP OR PLACE OF
ORGANIZATION British Virgin
Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH SOLE VOTING POWER 276,999 SHARED VOTING POWER 0 SOLE DISPOSITIVE POWER 276,999 SHARED DISPOSITIVE POWER 0 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 276,999 CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐ PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW 9 3.3%* TYPE OF REPORTING PERSON
(SEE INSTRUCTIONS) CO As of December 31, 2022, the reporting person beneficially owned 4.8% of the Issuers outstanding
common stock, based on 62,355,434 shares of the Issuers common stock outstanding as of December 8, 2022, as reported in the Issuers Definitive Proxy Statement filed with the Securities and Exchange Commission
(SEC) on December 8, 2022. The reporting person subsequently acquired 1,712,226 additional shares of the Issuers common stock. On January 17, 2023, the Issuer effected a one-for-seventeen (1:17) reverse stock split (the Reverse Stock Split). Following the Reverse Stock Split and as of the date of this filing, the reporting person beneficially owns
3.3% of the Issuers outstanding common stock. The percentage of shares beneficially owned as set forth in row 11 above was calculated based on 8,461,063 shares of common stock of the Issuer outstanding as of January 17, 2023, as reported
in the Issuers Current Report on Form 8-K filed with the SEC on January 17, 2023.
NAMES OF REPORTING PERSONS Ballaison Trust CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) ☐ (b) ☒ SEC USE ONLY CITIZENSHIP OR PLACE OF
ORGANIZATION New
Zealand NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH SOLE VOTING POWER 276,999 SHARED VOTING POWER 0 SOLE DISPOSITIVE POWER 276,999 SHARED DISPOSITIVE POWER 0 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 276,999 CHECK BOX IF THE AGGREGATE
AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐ PERCENT OF CLASS
REPRESENTED BY AMOUNT IN ROW 9 3.3%* TYPE OF REPORTING PERSON
(SEE INSTRUCTIONS) OO As of December 31, 2022, the reporting person beneficially owned 4.8% of the Issuers outstanding
common stock, based on 62,355,434 shares of the Issuers common stock outstanding as of December 8, 2022, as reported in the Issuers Definitive Proxy Statement filed with the SEC on December 8, 2022. The reporting person
subsequently acquired 1,712,226 additional shares of the Issuers common stock. On January 17, 2023, the Issuer effected the Reverse Stock Split. Following the Reverse Stock Split and as of the date of this filing, the reporting person
beneficially owns 3.3% of the Issuers outstanding common stock. The percentage of shares beneficially owned as set forth in row 11 above was calculated based on 8,461,063 shares of common stock of the Issuer outstanding as of January 17,
2023, as reported in the Issuers Current Report on Form 8-K filed with the SEC on January 17, 2023.
This Schedule 13G/A (#5), the Schedule 13G/A (#4) filed June 7, 2022, the Schedule 13G/A
(#3) filed February 8, 2022, the Schedule 13G/A (#2) filed February 12, 2021, the Schedule 13G/A (#1) filed February 20, 2020, and the initial Schedule 13G filed September 4, 2018, collectively, (the Schedule
13G) relate to shares of Common Stock, $0.001 par value per share (the Common Stock), of Aceragen, Inc. (formerly Idera Pharmaceuticals, Inc.), a Delaware corporation (the Issuer).
Castellina Ventures Ltd. (Castellina) is a limited company organized under the laws of the British Virgin
Islands whose principal business address and principal office address is 325 Waterfront Drive, Omar Hodge Building, 2nd Floor, Wickhams Cay, Road Town, Tortola, British Virgin Islands. The Ballaison Trust is the sole shareholder of Castellina
(The Ballaison Trust). The Ballaison Trust is a trust established under the laws of New Zealand whose principal
business address and principal office address is 14, rue de la Corraterie, PO Box 5209, CH-1211 Geneva 11. M&D Trustees SA is the trustee of The Ballaison Trust. The Ballaison Trust was established for the
principal purpose of holding and preserving assets for the benefit of its beneficiaries. Item 1(a). Name of Issuer: Aceragen, Inc. Item 1(b). Address of Issuers
Principal Executive Offices: 505 Eagleview Blvd., Suite 212, Exton, Pennsylvania 19341 Item 2(a). Name of Person Filing: (i) Castellina
Ventures Ltd. and (ii) The Ballaison Trust Item 2(b). Address of Principal Business Office or, if None, Residence: The address of the principal business office of the Reporting Persons: The address for Castellina is 325 Waterfront Drive, Omar Hodge Building, 2nd Floor, Wickhams Cay, Road Town, Tortola, British Virgin Islands and the
address for The Ballaison Trust if Rue de la Corraterie 14, PO Box 5209, 1211 Geneva 11. Item 2(c). Citizenship: Castellina is a limited company organized under the laws of the British Virgin Islands. The Ballaison Trust is a trust formed under the laws of New Zealand. Item 2(d). Title of Class of Securities: Common Stock, par value $0.001 per share Item 2(e).
CUSIP Number: 00445F109 Item 3.
Not Applicable.
Item 4. Ownership. Castellina Ventures Ltd. and The Ballaison Trust may be each deemed to beneficially own the following: Amount beneficially owned: 276,999 Percent of class: 3.3% Number of shares as to which such person has: Sole power to vote or to direct the vote: 276,999 Shared power to vote or to direct the vote:
--0-- Sole power to dispose or to direct the disposition of: 276,999 Shared power to dispose or to direct the disposition of: --0-- The percentage of shares beneficially owned was calculated based on 8,461,063 shares of
common stock of the Issuer outstanding as of January 17, 2023, as reported in the Issuers Current Report on Form 8-K filed with the SEC on January 17, 2023. Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of
more than five percent of the class of securities, check the following. ☒ Item 6. Ownership of More than Five Percent on Behalf of
Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control
Person. Not applicable. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of
Dissolution of Group. Not applicable. Item 10. Certifications. By signing
below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §
240.14a-11.
SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 14, 2023 /s/ Edward Martin-Du Pan /s/ Edward Martin-Du Pan /s/ Alexis Dubois-Ferrière
CUSIP No. 00445F109
SC 13G/A
Page
2
of 6 Pages
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
*
CUSIP No. 00445F109
SC 13G/A
Page
3
of 6 Pages
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
*
CUSIP No. 00445F109
SC 13G/A
Page
4
of 6 Pages
CUSIP No. 00445F109
SC 13G/A
Page
5
of 6 Pages
(a)
(b)
(c)
(i)
(ii)
(iii)
(iv)
CUSIP No. 00445F109
SC 13G/A
Page
6
of 6 Pages
CASTELLINA VENTURES LTD.
By:
Name: Edward Martin-Du Pan
Title: Director
BALLAISON TRUST
By: M&D Trustees SA, as Trustee
By:
Name: Edward Martin-Du Pan
Title: Director
By:
Name: Alexis Dubois-Ferrière
Title: Director
1 Year Idera Pharmaceuticals Chart |
1 Month Idera Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions